Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
The goal of this clinical trial is to compare a 2-dose and 3-dose series of 9vHPV vaccine among 27-45-year-old females to assess if 2 doses elicit a noninferior immune response. Participants will be randomized 1:1 to either the 2-dose group or the 3-dose group and asked to provide 4 blood samples over a period of 12 months. All 2-dose participants will be offered a 3rd dose after the final blood draw,12 months after their initial vaccination.
Conditions:
🦠 Immunization 🦠 HPV Infection 🦠 Human Papillomavirus
🗓️ Study Start (Actual) 18 January 2023
🗓️ Primary Completion (Estimated) August 2026
✅ Study Completion (Estimated) August 2027
👥 Enrollment (Estimated) 618
🔬 Study Type INTERVENTIONAL
📊 Phase PHASE4
Locations:
📍 Galveston, Texas, United States

📋 Eligibility Criteria

Description

    Inclusion Criteria:

    • 1. Females 27-45 years old.
    • 2. Ability to give informed consent.
    • 3. Has not received any prior doses of the HPV vaccine. This will be verified by the person and state registry (Immtrac), as well as the person's electronic medical record.
    • 4. Reliable telephone access for the duration of the project.
    • 5. Can read and speak in either English or Spanish.
    • 6. Identified source of funding for vaccine such as Medicaid, private health insurance, Texas Healthy Women program, etc.
    • 7. Reports consistent use of reliable birth control and plans to continue its use through study month 13.

    Exclusion Criteria:

    • 1. Currently pregnant or plans to become pregnant or donate eggs in the next 13 months. Any subjects with positive pregnancy tests at the initial visit will be disqualified from the study and advised to seek prenatal care.
    • 2. Has an immunodeficiency or autoimmune disease such as HIV infection, lymphoma, leukemia, lupus, rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
    • 3. Currently receiving treatment or medication that can suppress immune function including radiation therapy, chemotherapy, cyclosporin, leflunomide (Arava), TNF-α antagonists, monoclonal antibody therapies (including rituximab \[Rituxan\]), intravenous gamma globulin (IVIG), antilymphocyte sera, other therapy known to interfere with the immune response, or systemic corticosteroids (by mouth or intramuscular injection). Those using or have used steroids that are inhaled, placed in the eye, applied on the skin, or injected into the joint/soft tissue will be considered eligible for the study.
    • 4. History of splenectomy
    • 5. Known allergies to any vaccine components, including aluminum, yeast or Benzonase.
    • 6. Febrile at ≥100°F in the 24 hours prior to vaccination. The patients may be rescheduled for a later date.
    • 7. History of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
    • 8. History of \>10 sexual partners in their lifetime at time of enrollment
    • 9. Plans to move out of the Galveston/Houston area in the 13 months following study entry.
Ages Eligible for Study: 27 Years to 45 Years (ADULT)
Sexes Eligible for Study: FEMALE
Accepts Healthy Volunteers: Yes

🗓️ Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

  • First Submitted 19 December 2022
  • First Submitted that Met QC Criteria 21 December 2022
  • First Posted 5 January 2023

Study Record Updates

  • Last Update Submitted that Met QC Criteria 3 April 2024
  • Last Update Posted 4 April 2024
  • Last Verified April 2024